We’re very proud of what we have accomplished during the past 20 years in translating basic gene expression technologies into a unique platform that is used by more than 100 leading companies worldwide.
2021
Best Workplace in Switzerland by Great Placed to Work® for fourth consecutive year
Names New Chief Business Officer
2020
Best Workplace in Switzerland by Great Placed to Work® for third consecutive year
Names New Chief Executive Officer
Expands scientific and operational leadership teams
2019
Named among “Best Workplaces in Switzerland” for second consecutive year
Fifth SUREtechnology Platform™-generated product receives market approval
Biosimilar becomes sixth SUREtechnology Platform™-generated marketed product
2018
Names Chief Financial Officer
Achieves 100th commercial license agreement
Invests $2 million in state-of-the art laboratory equipment; expands workforce
Swiss Biotech Association honors Selexis among inaugural Swiss Biotech Success Stories
Earns “Best Companies to Work for in Switzerland 2018” certification
Collaborates with Berkeley Lights to accelerate cell line development with Beacon® optofluidic platform
KBI Biopharma Inc. and Selexis form joint Scientific Advisory Board
2017
Opens new world-class laboratory facility and corporate headquarters in Geneva, Switzerland
Acquired by JSR Life Sciences
2015
First Selexis SUREtechnology-generated therapeutic monoclonal antibody approved
Uses next-generation sequencing to fully sequence Selexis-generated research cell banks
2013
Launches SURE CHO-Mplus Libraries™
Sells potential milestone and royalty payments to Ligand Pharmaceuticals
2011
Doubles cell line development laboratory space in Geneva, Switzerland
Completes sequencing of the Selexis SURE CHO-M genome along with scientists at University of Lausanne
Celebrates 10-year anniversary
Launches SUREvariant Screening™
Forms Scientific Advisory Board headed by Sir Gregory Paul Winter, CBE, FRS, FMed Sci
2007
Expands European production and business operations with new facilities and staff
Establishes U.S. subsidiary, Selexis, Inc.
2005
Opens new R&D facility in Plan-les-Ouates, Switzerland
2002
Dr. Fisch wins New Entrepreneurs for Technology and Sciences (NETS) Best Prize
2001
Company co-founded by Dr. Fisch and Prof. Nicolas Mermod, Ph.D., using winning funds from De Vigier Prize
2000
Igor Fisch, Ph.D., wins the De Vigier Prize for the best biotech idea of Y2K
